Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Leukemia. 2019 Jul 29;33(12):2971–2974. doi: 10.1038/s41375-019-0529-2

Figure 1. ROC-325 inhibits autophagy and diminishes AML cell viability.

Figure 1.

(a) ROC-325 induces the formation of autophagosomes with undegraded cargo. MV4–11 AML cells were treated with 1 μM ROC-325 for 6 h or 24 h as indicated and autophagosomes were visualized using transmission electron microscopy. (b) Treatment with ROC-325 increases LC3B and p62. MV4–11 and MOLM-13 cells were treated with the indicated concentrations of ROC-325 for 24 h. Protein expression was quantified by immunoblotting. (c) ROC-325 selectively antagonizes AML cell viability. Normal bone marrow CD34+ cells and a panel of AML cell lines were treated with ROC-325 as indicated for 72 h. Cell viability was quantified by MTT assay. N = 3, Mean ± SD.